Earlier Autism Diagnosis Possible for Some Children Based on Metabolic Biomarkers in Blood, New Research Shows
Sep 6, 2018A paper by NeuroPointDX scientists, along with our collaborator Dr. David Amaral (University of California – Davis MIND Institute), published in Biological Psychiatry, is the first publication resulting from the Children’s Autism Metabolome Project (CAMP), the largest study of the metabolism of children with autism spectrum disorder. Thomas Frazier, Chief Scientific Officer of Autism Speaks,
Stemina to Present Poster at Teratology Society Annual Meeting
Jun 15, 2018Stemina’s Jessica Palmer to Present Poster at Teratology Society Annual Meeting Jessica Palmer, Stemina’s Associate Director of Toxicology, will present a poster at the Teratology Society Annual Meeting, held June 23-27, 2018 in Clearwater, Florida. Anyone interested in developmental toxicity assays is encouraged to attend. A Human Pluripotent Stem Cell-Based Assay Accurately Predicts the Developmental
Stemina Launches Cardiotoxicity Assay, Presents Sponsored Session, Poster at SOT’s Annual Meeting & ToxExpo 2018
Feb 20, 2018Stemina Launches Cardiotoxicity Assay, Presents Sponsored Session, Poster at SOT’s Annual Meeting & ToxExpo 2018 The Stemina team will attend the Society of Toxicology’s Annual Meeting and ToxExpo in San Antonio, Texas from March 11-15, 2018. We are excited to share information about our new cardiotoxicity assay, Cardio quickPredict, now commercially-available for the first time.
NeuroPointDX Announces Validation of First-Generation Autism Diagnostic Panel
Jan 18, 2018NeuroPointDX, the neurodevelopmental disorders division of Stemina Biomarker Discovery, has validated 12 metabolic subtypes of autism spectrum disorder. The diagnostic blood test for ASD will be available later this year. CEO Elizabeth Donley says, “This is a historic moment, not just for Stemina and NeuroPointDX, but for our knowledge and understanding of autism.” Read the
Stemina to Present a Poster at American College of Toxicology Annual Meeting
Oct 25, 2017Jessica Palmer, Stemina’s Associate Director of Toxicology, will present a poster at the American College of Toxicology’s 38th Annual Meeting, held November 5-8, 2017 in Palm Springs, California. Anyone interested in cardiotoxicity assays is encouraged to attend. Development of a Targeted Biomarker Assay to Predict Cardiotoxicity Potential Using Metabolomics and Human Induced Stem Cell-Derived Cardiomyocytes
Stemina Featured as an Innovative Madison-Area Business
Sep 27, 2017In collaboration with the Greater Madison Chamber of Commerce, the Wisconsin State Journal produced a special section to “highlight and explore innovation efforts.” Each company’s profile is written by its leader. Stemina’s CEO, Elizabeth Donley, penned our article and also graces the cover of the section. Read Stemina’s profile Explore other companies in the section
Stemina Biomarker Discovery Prepares to Commercialize Autism Diagnostic Products; Appoints New Board Member, Heiner Dreismann, PhD, Former Head of Roche Molecular Diagnostics
Aug 25, 2017Dr. Driesmann, a leader in the diagnostics industry, will guide Stemina’s commercialization strategy. Read the full press release.
Stemina’s Jessica Palmer to Present at Teratology Society Annual Meeting
Jun 14, 2017Jessica Palmer, Stemina’s Associate Director of Toxicology, will present at the Teratology Society’s 57th Annual Meeting, held June 24-28, 2017 in Denver. Anyone interested in developmental toxicity assays is encouraged to attend. Prediction of Developmental Toxicity Potential by In Vivo Exposures with a Biomarker-Based Human Pluripotent Stem Cell Assay This presentation is part of Platform
Stemina to Present Sponsored Session, Poster at SOT’s Annual Meeting & ToxExpo 2017
Feb 20, 2017Stemina Biomarker Discovery will be well represented at the Society of Toxicology’s 56th Annual Meeting and ToxExpo. In addition to participating in SOT as an exhibitor (booth 2506), Stemina’s Jessica Palmer, Associate Director of Toxicology, will present new research in two sessions: Poster session: Monday, March 13th | 9:30 AM – 12:45 PM | P331
NeuroPointDX Partners with Ovid Therapeutics to Identify Biomarkers for Angelman Syndrome
Feb 9, 2017Together, Ovid and NeuroPointDX will use metabolomics data to better understand the rare neuro-genetic disorder known as Angelman Syndrome. NeuroPointDX’s metabolomics technology will be used in Ovid’s phase 2 STARS trial of its drug candidate, OV101.